Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CLBT Stock Summary
Top 10 Correlated ETFs
CLBT
In the News
VNT vs. CLBT: Which Stock Is the Better Value Option?
Investors with an interest in Technology Services stocks have likely encountered both Vontier Corporation (VNT) and Cellebrite DI Ltd. (CLBT). But which of these two stocks presents investors with the better value opportunity right now?
Is Cellebrite DI Ltd. (CLBT) Outperforming Other Business Services Stocks This Year?
Here is how Cellebrite DI Ltd. (CLBT) and Viant Technology (DSP) have performed compared to their sector so far this year.
Cellebrite DI Ltd. (CLBT) is a Great Momentum Stock: Should You Buy?
Does Cellebrite DI Ltd. (CLBT) have what it takes to be a top stock pick for momentum investors?
VNT vs. CLBT: Which Stock Should Value Investors Buy Now?
Investors with an interest in Technology Services stocks have likely encountered both Vontier Corporation (VNT) and Cellebrite DI Ltd. (CLBT). But which of these two stocks presents investors with the better value opportunity right now?
Are Business Services Stocks Lagging Cellebrite DI Ltd. (CLBT) This Year?
Here is how Cellebrite DI Ltd. (CLBT) and Credo Technology Group Holding Ltd.
Surging Earnings Estimates Signal Upside for Cellebrite DI Ltd. (CLBT) Stock
Cellebrite DI Ltd. (CLBT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Cellebrite DI Ltd. (CLBT) Is Up 20.78% in One Week: What You Should Know
Does Cellebrite DI Ltd. (CLBT) have what it takes to be a top stock pick for momentum investors?
Cellebrite DI Ltd. (CLBT) Q4 2023 Earnings Call Transcript
Cellebrite DI Ltd. (CLBT) Q4 2023 Earnings Call Transcript
Cellebrite: Growth, Profits, And Consistency
Cellebrite DI Ltd. specializes in digital forensics data extraction and management, catering to government organizations and police forces. The company has a strong moat with high customer retention and barriers to entry in the industry. I believe Cellebrite is worth $15+ versus the current stock price of $9.
Will Cellebrite DI Ltd. (CLBT) Beat Estimates Again in Its Next Earnings Report?
Cellebrite DI Ltd. (CLBT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CLBT Financial details
CLBT Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.92 | 1.04 | 1.54 | 1.68 | 1.71 | |
Net income per share | -0.01 | 0.03 | 0.45 | 0.75 | -0.43 | |
Operating cash flow per share | 0.09 | 0.36 | 0.23 | 0.13 | 0.51 | |
Free cash flow per share | 0.05 | 0.32 | 0.17 | 0.07 | 0.47 | |
Cash per share | 1.07 | 1.27 | 1.13 | 1.14 | 1.59 | |
Book value per share | 0.31 | 0.34 | -0.46 | 0.46 | 0.18 | |
Tangible book value per share | 0.31 | 0.26 | -0.7 | 0.22 | -0.02 | |
Share holders equity per share | 0.31 | 0.34 | -0.46 | 0.46 | 0.18 | |
Interest debt per share | 0 | -0.01 | -0.01 | 0.84 | 0.03 | |
Market cap | 1.81B | 1.97B | 1.28B | 704.31M | 1.65B | |
Enterprise value | 1.73B | 1.84B | 1.14B | 632.02M | 1.47B | |
P/E ratio | -963.78 | 340.92 | 17.98 | 5.83 | -20.31 | |
Price to sales ratio | 10.52 | 10.11 | 5.21 | 2.6 | 5.07 | |
POCF ratio | 112.07 | 29.63 | 35.61 | 34.23 | 16.86 | |
PFCF ratio | 182.19 | 32.67 | 45.95 | 61.29 | 18.34 | |
P/B Ratio | 30.73 | 30.89 | -17.5 | 9.54 | 48.13 | |
PTB ratio | 30.73 | 30.89 | -17.5 | 9.54 | 48.13 | |
EV to sales | 10.08 | 9.45 | 4.62 | 2.34 | 4.53 | |
Enterprise value over EBITDA | 630.33 | 118.52 | 54.41 | 61.73 | 34.02 | |
EV to operating cash flow | 107.33 | 27.7 | 31.56 | 30.71 | 15.06 | |
EV to free cash flow | 174.48 | 30.54 | 40.72 | 55 | 16.39 | |
Earnings yield | 0 | 0 | 0.06 | 0.17 | -0.05 | |
Free cash flow yield | 0.01 | 0.03 | 0.02 | 0.02 | 0.05 | |
Debt to equity | 0 | -0.04 | 0.04 | 0.21 | 0.15 | |
Debt to assets | 0 | -0.01 | -0.01 | 0.04 | 0.01 | |
Net debt to EBITDA | -27.87 | -8.28 | -6.98 | -7.06 | -4.06 | |
Current ratio | 2.64 | 2.03 | 1.46 | 1.42 | 1.66 | |
Interest coverage | 0 | 6.48 | 24.51 | 0.01 | 0 | |
Income quality | -8.6 | 11.5 | 0.5 | 0.17 | -1.2 | |
Dividend Yield | 0.01 | 0.01 | 0.08 | 0 | 0 | |
Payout ratio | -13.33 | 1.73 | 1.4 | 0 | 0 | |
Sales general and administrative to revenue | 0.17 | 0.15 | 0.19 | 0.15 | 0 | |
Research and developement to revenue | 0.27 | 0.28 | 0.27 | 0.3 | 0.26 | |
Intangibles to total assets | 0 | 0.04 | 0.11 | 0.09 | 0.07 | |
Capex to operating cash flow | -0.38 | -0.09 | -0.22 | -0.44 | -0.08 | |
Capex to revenue | -0.04 | -0.03 | -0.03 | -0.03 | -0.02 | |
Capex to depreciation | -1.52 | -1.05 | -1.14 | -0.99 | -0.79 | |
Stock based compensation to revenue | 0.07 | 0.04 | 0.03 | 0.05 | 0.06 | |
Graham number | 0.27 | 0.49 | 2.14 | 2.77 | 1.31 | |
ROIC | 0.03 | 0.08 | -0.16 | 0.01 | 0.74 | |
Return on tangible assets | -0.01 | 0.02 | 0.24 | 0.33 | -0.16 | |
Graham Net | 0.07 | -0.06 | -1.11 | -0.51 | -0.7 | |
Working capital | 162.72M | 164.89M | 86.64M | 88.15M | 168.26M | |
Tangible asset value | 58.83M | 47.73M | -111.41M | 35.78M | -3.21M | |
Net current asset value | 40.47M | 23.69M | -139.92M | -33.5M | -76.59M | |
Invested capital | 0 | -0.04 | 0.04 | 0.21 | 0.15 | |
Average receivables | 0 | 55.28M | 66.91M | 73.13M | 78.02M | |
Average payables | 0 | 5.04M | 7.14M | 7.08M | 28.87M | |
Average inventory | 0 | 4.36M | 5.63M | 8.34M | 10.06M | |
Days sales outstanding | 93.95 | 124.2 | 100.06 | 106.22 | 86.75 | |
Days payables outstanding | 54.61 | 45.55 | 81.87 | 33.17 | 364.29 | |
Days of inventory on hand | 40.35 | 45.81 | 55.84 | 73.19 | 68.16 | |
Receivables turnover | 3.88 | 2.94 | 3.65 | 3.44 | 4.21 | |
Payables turnover | 6.68 | 8.01 | 4.46 | 11 | 1 | |
Inventory turnover | 9.05 | 7.97 | 6.54 | 4.99 | 5.36 | |
ROE | -0.03 | 0.09 | -0.97 | 1.64 | -2.37 | |
Capex per share | -0.03 | -0.03 | -0.05 | -0.06 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.4 | 0.36 | 0.38 | 0.41 | 0.48 | |
Net income per share | 0.04 | -0.2 | -0.16 | 0.03 | -0.08 | |
Operating cash flow per share | 0.19 | 0.06 | 0.08 | 0.14 | 0.2 | |
Free cash flow per share | 0.18 | 0.06 | 0.08 | 0.14 | 0.18 | |
Cash per share | 0.99 | 1.02 | 1.19 | 1.29 | 1.56 | |
Book value per share | 0.4 | 0.2 | 0.09 | 0.19 | 0.18 | |
Tangible book value per share | 0.19 | 0.01 | -0.09 | 0 | 0.04 | |
Share holders equity per share | 0.4 | 0.2 | 0.09 | 0.19 | 0.18 | |
Interest debt per share | 0.08 | 0.27 | 0.25 | 0.09 | 0.03 | |
Market cap | 806.39M | 1.21B | 1.44B | 1.56B | 1.68B | |
Enterprise value | 734.1M | 1.12B | 1.34B | 1.44B | 1.51B | |
P/E ratio | 28.48 | -7.43 | -11.11 | 60.14 | -28.74 | |
Price to sales ratio | 10.89 | 16.94 | 18.75 | 18.57 | 18.1 | |
POCF ratio | 22.56 | 96.74 | 86.74 | 53.59 | 42.67 | |
PFCF ratio | 24.76 | 105.76 | 91.29 | 55.65 | 48.78 | |
P/B Ratio | 10.92 | 30.67 | 81.9 | 41.21 | 49.22 | |
PTB ratio | 10.92 | 30.67 | 81.9 | 41.21 | 49.22 | |
EV to sales | 9.92 | 15.76 | 17.49 | 17.09 | 16.22 | |
Enterprise value over EBITDA | 60.2 | 434.69 | 186.45 | 90.71 | 85.64 | |
EV to operating cash flow | 20.54 | 90 | 80.9 | 49.3 | 38.22 | |
EV to free cash flow | 22.54 | 98.39 | 85.13 | 51.2 | 43.7 | |
Earnings yield | 0.01 | -0.03 | -0.02 | 0 | -0.01 | |
Free cash flow yield | 0.04 | 0.01 | 0.01 | 0.02 | 0.02 | |
Debt to equity | 0.21 | 0.38 | 0.77 | 0.32 | 0.15 | |
Debt to assets | 0.04 | 0.04 | 0.03 | 0.03 | 0.01 | |
Net debt to EBITDA | -5.93 | -32.58 | -13.48 | -7.88 | -9.96 | |
Current ratio | 1.42 | 1.52 | 1.65 | 1.65 | 1.66 | |
Interest coverage | -16.91 | 0 | 0.13 | 2.03 | 0 | |
Income quality | 5.05 | -0.31 | -0.51 | 4.49 | -2.69 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.12 | 0.14 | 0.15 | 0.12 | 0.13 | |
Research and developement to revenue | 0.27 | 0.3 | 0.27 | 0.24 | 0.23 | |
Intangibles to total assets | 0.09 | 0.09 | 0.09 | 0.08 | 0.05 | |
Capex to operating cash flow | -0.09 | -0.09 | -0.05 | -0.04 | -0.13 | |
Capex to revenue | -0.04 | -0.01 | -0.01 | -0.01 | -0.05 | |
Capex to depreciation | -1.26 | -0.43 | -0.32 | -0.45 | -1.89 | |
Stock based compensation to revenue | 0.05 | 0.06 | 0.06 | 0.06 | -0.11 | |
Graham number | 0.59 | 0.96 | 0.57 | 0.36 | 0.55 | |
ROIC | 0.07 | 0 | 0.11 | 0.21 | 0.37 | |
Return on tangible assets | 0.02 | -0.11 | -0.08 | 0.01 | -0.03 | |
Graham Net | -0.44 | -0.57 | -0.6 | -0.57 | -0.68 | |
Working capital | 88.15M | 105.54M | 132.9M | 147.47M | 168.26M | |
Tangible asset value | 35.78M | 2.07M | -18.89M | -42K | 7.38M | |
Net current asset value | -33.5M | -63.05M | -70.93M | -64.69M | -76.59M | |
Invested capital | 0.21 | 0.38 | 0.77 | 0.32 | 0.15 | |
Average receivables | 83.67M | 74.18M | 65.39M | 65.38M | 73.41M | |
Average payables | 4.66M | 4.77M | 4.95M | 6.49M | 30.56M | |
Average inventory | 9.76M | 10.79M | 11.11M | 11.02M | 10.58M | |
Days sales outstanding | 95.77 | 87.93 | 71.82 | 74.37 | 74.77 | |
Days payables outstanding | 34.22 | 35.68 | 34.47 | 55.8 | 320.56 | |
Days of inventory on hand | 75.5 | 82.74 | 74.74 | 78.34 | 59.98 | |
Receivables turnover | 0.94 | 1.02 | 1.25 | 1.21 | 1.2 | |
Payables turnover | 2.63 | 2.52 | 2.61 | 1.61 | 0.28 | |
Inventory turnover | 1.19 | 1.09 | 1.2 | 1.15 | 1.5 | |
ROE | 0.1 | -1.03 | -1.84 | 0.17 | -0.43 | |
Capex per share | -0.02 | -0.01 | 0 | -0.01 | -0.03 |
CLBT Frequently Asked Questions
What is Cellebrite DI Ltd. stock symbol ?
Cellebrite DI Ltd. is a IL stock and trading under the symbol CLBT
What is Cellebrite DI Ltd. stock quote today ?
Cellebrite DI Ltd. stock price is $11.08 today.
Is Cellebrite DI Ltd. stock public?
Yes, Cellebrite DI Ltd. is a publicly traded company.